Skip to main content
DBD
NYSE Technology

Diebold Nixdorf Reports Strong Q1 2026 Results, Triples Free Cash Flow, Reaffirms Outlook

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
8
Price
$82.5
Mkt Cap
$2.888B
52W Low
$43
52W High
$89.05
Market data snapshot near publication time

Summary

Diebold Nixdorf announced robust first-quarter 2026 financial results, showcasing significant growth in revenue, adjusted EPS, and a more than tripling of free cash flow, while reaffirming its full-year guidance.


Key Events

  • Strong Q1 Financial Performance

    Diebold Nixdorf reported a 6% year-over-year revenue increase to $891.8 million, with GAAP net income turning positive at $5.5 million (from a loss of $7.5 million) and adjusted EPS growing 81% to $0.67. Adjusted EBITDA also increased by 13.5% to $99.1 million.

  • Significant Free Cash Flow Growth

    The company generated $20.7 million in free cash flow, more than tripling the prior year's $6.1 million, marking the sixth consecutive quarter of positive cash generation.

  • Material Share Repurchases

    Diebold Nixdorf repurchased approximately $55 million of its common shares during the first quarter, with $117 million remaining under its $200 million share repurchase program initiated earlier this year.

  • Reaffirmed Full-Year Outlook

    Management reaffirmed its 2026 financial outlook, including total revenue of $3.86B - $3.94B, Adjusted EBITDA of $510M - $535M, Free Cash Flow of $255M - $270M, and Adjusted EPS of $5.25 - $5.75.


Analysis

Diebold Nixdorf's first-quarter 2026 results demonstrate robust operational execution and continued financial improvement, building on the strong turnaround reported in the 2025 10-K. The significant increase in free cash flow for the sixth consecutive quarter highlights improved liquidity and cash generation capabilities. The substantial share repurchases underscore management's commitment to returning capital to shareholders. Reaffirming the full-year guidance after such a strong quarter signals confidence in sustained performance, while the Fitch rating and S&P SmallCap 600 inclusion provide external validation of the company's strengthening financial profile.

At the time of this filing, DBD was trading at $82.50 on NYSE in the Technology sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $43.00 to $89.05. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DBD - Latest Insights

DBD
Apr 30, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
DBD
Apr 17, 2026, 4:28 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
DBD
Apr 10, 2026, 4:04 PM EDT
Filing Type: 4
Importance Score:
7
DBD
Feb 12, 2026, 4:38 PM EST
Filing Type: 10-K
Importance Score:
9
DBD
Feb 12, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
DBD
Jan 20, 2026, 4:11 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
DBD
Jan 20, 2026, 4:10 PM EST
Filing Type: 4
Importance Score:
7
DBD
Jan 15, 2026, 4:40 PM EST
Filing Type: 144
Importance Score:
7